Market research
CRMD CorMedix Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 639M
- P/E ratio
- 4.0
- Analyst target
- 15.3333
- Dividend yield
- Not available
- Beta
- 1.41
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 639M
- P/E ratio
- 4.0
- Analyst target
- 15.3333
- Dividend yield
- Not available
- Beta
- 1.41
About
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Research context
CorMedix Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CRMD discussion.
5 years, 6 months ago
CorMedix Inc is currently in a long term downtrend where the price is trading 17.8% below its 200 day moving average.
From a valuation standpoint, the stock is 16.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1124.7.
CorMedix Inc's total revenue rose by 124.9% to $56K since the same quarter in the previous year.
Its net income has dropped by 14.8% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.3% to $-6M since the same quarter in the previous year.
Based on the above factors, CorMedix Inc gets an overall score of 2/5.